Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) ...
Jun 3, 2022
0
35
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma.
May 8, 2019
0
70
Researchers in Germany have found a new way to exploit the differences between cancer cells and normal cells that could lead to new treatments.
Jun 13, 2013
0
0
Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma Society, ...
Oct 10, 2012
0
0
A new research paper was published in Oncotarget entitled, "Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface."
Apr 16, 2024
0
0
Patients with some types of lymphoma that become resistant to standard treatments may benefit from a therapy that University of Wisconsin–Madison researchers are evaluating after they discovered a key process that fuels ...
Mar 16, 2024
0
48
Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, according to a new study published in Blood Advances.
Feb 5, 2024
0
0
Proteasomes are protein-degrading complexes that are important for cancer cell survival. Proteasome inhibitors are commonly used to treat diseases such as multiple myeloma and mantle cell lymphoma. Proteasomes have three ...
Dec 14, 2023
0
15
Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study published ...
Aug 17, 2023
0
29
A new research paper titled "Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma" has been published in Oncotarget.
Dec 13, 2022
0
3
